BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-2548-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees51
OptionableNot Optionable
BIOLINERX LTD/S (NASDAQ:BLRX) Frequently Asked Questions
What is BIOLINERX LTD/S's stock symbol?
BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX."
How were BIOLINERX LTD/S's earnings last quarter?
BIOLINERX LTD/S (NASDAQ:BLRX) issued its earnings results on Thursday, August, 11th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). View BIOLINERX LTD/S's Earnings History.
When is BIOLINERX LTD/S's next earnings date?
What price target have analysts set for BLRX?
3 analysts have issued 12-month target prices for BIOLINERX LTD/S's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate BIOLINERX LTD/S's stock price to reach $3.00 in the next year. This suggests a possible upside of 650.0% from the stock's current price. View Analyst Price Targets for BIOLINERX LTD/S.
What is the consensus analysts' recommendation for BIOLINERX LTD/S?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLINERX LTD/S.
What are Wall Street analysts saying about BIOLINERX LTD/S stock?
Here are some recent quotes from research analysts about BIOLINERX LTD/S stock:
- 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (11/14/2018)
- 2. Maxim Group analysts commented, "BioLineRx reported 3Q18 with a net loss of ($6.2M) and ended the quarter with $35M in cash on the balance sheet. We estimate a runway to late 2019." (11/8/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, BL-8040. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (7/30/2018)
Has BIOLINERX LTD/S been receiving favorable news coverage?
News coverage about BLRX stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIOLINERX LTD/S earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are some of BIOLINERX LTD/S's key competitors?
Some companies that are related to BIOLINERX LTD/S include Molecular Templates (MTEM), Zafgen (ZFGN), Nature's Sunshine Products (NATR), Ardelyx (ARDX), Poxel (PXXLF), Syndax Pharmaceuticals (SNDX), VBI Vaccines (VBIV), Mersana Therapeutics (MRSN), Marinus Pharmaceuticals (MRNS), Ocular Therapeutix (OCUL), BELLUS Health (BLUSF), AgeX Therapeutics (AGE), Proteostasis Therapeutics (PTI), Menlo Therapeutics (MNLO) and CytoDyn (CYDY).
Who are BIOLINERX LTD/S's key executives?
BIOLINERX LTD/S's management team includes the folowing people:
- Mr. Philip A. Serlin CPA, MBA, Chief Exec. Officer (Age 59)
- Ms. Mali Zeevi CPA, Chief Financial Officer (Age 43)
- Dr. Ella Sorani, VP R&D (Age 51)
- Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 44)
- Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 67)
Who are BIOLINERX LTD/S's major shareholders?
BIOLINERX LTD/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ETF Managers Group LLC (0.35%), Menta Capital LLC (0.07%) and Two Sigma Securities LLC (0.05%).
Which major investors are buying BIOLINERX LTD/S stock?
BLRX stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Menta Capital LLC and Two Sigma Securities LLC.
How do I buy shares of BIOLINERX LTD/S?
Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOLINERX LTD/S's stock price today?
One share of BLRX stock can currently be purchased for approximately $0.40.
How big of a company is BIOLINERX LTD/S?
BIOLINERX LTD/S has a market capitalization of $42.60 million. The biotechnology company earns $-24,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. BIOLINERX LTD/S employs 51 workers across the globe.
What is BIOLINERX LTD/S's official website?
How can I contact BIOLINERX LTD/S?
BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]
MarketBeat Community Rating for BIOLINERX LTD/S (NASDAQ BLRX)
MarketBeat's community ratings are surveys of what our community members think about BIOLINERX LTD/S and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
